The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 442-449

  Wiseman, A C ^a   McCague, K ^b   Kim, Y ^b   Geissler, F ^b   Cooper, M ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Everolimus; GFR; graft survival; proteinuria

Indexed keywords

EVEROLIMUS; MYCOPHENOLIC ACID;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME;

ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYCOPHENOLIC ACID; PROTEINURIA; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873080842     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04334.x     Document Type: Article

References (21)

1. Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5: 2281-2288.
2. Fernandez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002; 73: 1345-1348.
3. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7: 2748-2756.
4. Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438-444.
5. Amer H, Cosio FG,. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2490-2492.
6. Stallone G, Infante B, Grandaliano G, Gesualdo L,. Management of side effects of sirolimus therapy. Transplantation 2009; 87 (Suppl 8): S23-S26.
7. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8: 854-861.
8. Diekmann F, Gutierrez-Dalmau A, Lopez S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol Dial Transplant 2007; 22: 2316-2321.
9. Letavernier E, Bruneval P, Vandermeersch S, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630-638.
10. Biancone L, Bussolati B, Mazzucco G, et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant; 10: 2270-2278.
11. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int; 79: 897-907.
12. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet; 377: 837-847.
13. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM,. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875.
14. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
15. Tedesco, Silva H, Jr., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant; 10: 1401-1413.
16. Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6: 1660-1665.
17. D'Cunha PT, Parasuraman R, Venkat KK,. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant 2005; 5: 351-355.
18. Knoll GA,. Proteinuria in kidney transplant recipients: Prevalence, prognosis, and evidence-based management. Am J Kidney Dis 2009; 54: 1131-1144.
19. Sancho Calabuig A, Pallardo Mateu LM, Avila Bernabeu AI, et al. Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival. Transplant Proc 2009; 41: 2122.
20. Sancho A, Gavela E, Avila A, et al. Risk factors and prognosis for proteinuria in renal transplant recipients. Transplant Proc 2007; 39: 2145-2147.
21. Chung J, Park SK, Park JS, Kim SC, Han DJ, Yu E,. Glomerulonephritis is the major cause of proteinuria in renal transplant recipients: Histopathologic findings of renal allografts with proteinuria. Clin Transplant 2000; 14: 499-504.